Nylia 1/35 and Memory loss - a phase IV clinical study of FDA data
Summary:
We study 214,027 people who take Nylia 1/35 or have Memory loss. No report of Memory loss is found in people who take Nylia 1/35.
The phase IV clinical study is created by eHealthMe based on reports from the FDA, and is updated regularly.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
No report is found.
What is Nylia 1/35?
Nylia 1/35 has active ingredients of ethinyl estradiol; norethindrone.
What is Memory Loss?
Memory loss is found to be associated with 4,076 drugs and 4,140 conditions by eHealthMe.
Do you take Nylia 1/35 and have Memory loss?
Check whether Memory loss is associated with a drug or a conditionHow to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related studies
How severe was Memory loss and when was it recovered:
Expand to all the drugs that have ingredients of ethinyl estradiol; norethindrone:
Alternative drugs to, pros and cons of Nylia 1/35:
Memory loss treatments and more:
- Memory loss (214,027 reports)
COVID vaccines that are related to Memory loss:
- Memory loss in Moderna COVID Vaccine
- Memory loss in Pfizer BioNTech Covid Vaccine
- Memory loss in Johnson and Johnson Covid Vaccine
All the drugs that are associated with Memory loss:
All the conditions that are associated with Memory loss:
How the study uses the data?
The study uses data from the FDA. It is based on ethinyl estradiol; norethindrone (the active ingredients of Nylia 1/35) and Nylia 1/35 (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Levetiracetam and Rifadin drug interaction - 3 seconds ago
- Gravol and Mucous Stools - 10 seconds ago
- Lenalidomide and Drug Level Increased - 23 seconds ago
- Ifosfamide and Purpura Fulminans - 28 seconds ago
- Procysbi and Muscle Spasms - 28 seconds ago
- Aloxi and Photophobia - 29 seconds ago
- Ranitidine Hydrochloride and Enzyme Abnormality - 31 seconds ago
- Lovaza and Gas Gangrene - 34 seconds ago
- Sevoflurane and Gastroesophageal Reflux Disease - 40 seconds ago
- Promethegan and Levetiracetam drug interaction - 42 seconds ago